

XXV ANNUAL MEETING OF THE LATIN AMERICAN ASSOCIATION FOR THE STUDY OF THE LIVER (ALEH, for its acronym in Spanish)

September 20-23, 2018
Punta Cana, República Dominicana

ORAL

O-1

TRACKING OF VACCINE ESCAPE MUTATIONS IN PATIENTS WITH CHRONIC HBV IN TWO BRAZILIAN REGIONS

PACHECO SR,^{1,2} SCHINONI MI,² MAGALHÃES MIA,² ZARIFE MAS,² STOCKER A,² PARANÁ R,² REIS MG,¹ SILVA LK¹
¹ CENTRO DE PESQUISA GONÇALO MONIZ/LABORATÓRIO DE PATOLOGIA E BIOLOGIA MOLECULAR FIOCRUZ-BA.
² UNIVERSIDADE FEDERAL DA BAHIA/UFBA-SERVIÇO DE GASTROHEPATOLOGIA.

O-2

SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA PROMOTES CANCER DIAGNOSIS AT EARLY STAGES AND IMPROVES SURVIVAL EMPLOYING BOTH, "LOCAL" OR "NON-LOCAL" ULTRASOUND

PIÑERO F,^{1,11,12} MARCIANO S,² FERNÁNDEZ N,⁵ SILVA J,¹⁰ ZAMBELO Y,⁸ COBOS M,⁴ ZEREGA A,⁹ RIDRUEJO E,³ MIGUEZ C,⁶ AMEIGEIRAS B,¹⁴ D'AMICO C,¹³ GAITE L,⁷ BERMÚDEZ C,² ROSALES C,¹⁰ ROMERO G,⁶ MCCORMACK L,⁴ REGGIARDO V,⁸ COLOMBATO L,⁵ GADANO A,² RUBINSTEIN F,¹⁵ SILVA M¹
¹ HOSPITAL UNIVERSITARIO AUSTRAL, UNIVERSIDAD AUSTRAL SCHOOL OF MEDICINE, ARGENTINA.
² HOSPITAL ITALIANO FROM BUENOS AIRES.
³ CENTRO DE EDUCACIÓN MÉDICA E INVESTIGACIONES CLÍNICAS NORBERTO QUIRNO (CEMIC).
⁴ HOSPITAL ALEMÁN FROM BUENOS AIRES.
⁵ HOSPITAL BRITÁNICO FROM BUENOS AIRES.
⁶ HOSPITAL UDAONDO, BUENOS AIRES.
⁷ CLÍNICA DE NEFROLOGÍA FROM SANTA FE.
⁸ HOSPITAL DEL CENTENARIO, ROSARIO, SANTA FE.
⁹ HOSPITAL PRIVADO FROM CÓRDOBA.
¹⁰ HOSPITAL G RAWSON, SAN JUAN.
¹¹ SANATORIO TRINIDAD SAN ISIDRO, BUENOS AIRES.
¹² CLÍNICA PRIVADA SAN FERNANDO, BUENOS AIRES.
¹³ CENTRO ESPECIALIDADES MÉDICAS AMBULATORIAS (CEMA), MAR DEL PLATA, BUENOS AIRES.
¹⁴ HOSPITAL RAMOS MEJÍA, CIUDAD DE BUENOS AIRES.
¹⁵ INSTITUTO DE EFECTIVIDAD CLÍNICA Y SANITARIA (IECS), DEPARTAMENTO DE DESARROLLO ACADÉMICO, HOSPITAL UNIVERSITARIO AUSTRAL.

O-3

FIRST 1,000 PATIENTS WITH HEPATITIS C TREATED WITH DIRECT-ACTING ANTI VIRAL DRUGS IN ARGENTINA

SOLARI J,* CORONEL E,* AQUINO R,* ROITMAN K,* MARTÍNEZ-MADRID D,* VIDIÉLLA G,* VILA M,** PAPALE R,*** CARRANZA J,*** MAULEN S****
* PROGRAMA NACIONAL DE CONTROL DE LAS HEPATITIS, MINISTERIO DE SALUD.
** ORGANIZACIÓN PANAMERICANA DE LA SALUD, ARGENTINA.
*** ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA.
**** DIRECTOR DE SIDA, MINISTERIO DE SALUD DE LA NACIÓN.

O-4

A SIMPLE SCORE TO SELECT SORAFENIB TREATMENT CANDIDATES: A REPORT FROM THE SOUTH AMERICAN LIVER RESEARCH NETWORK

LEATHERS J,¹ BALDERRAMO D,² PRIETO J,³ DIEHL F,² GONZALEZ-BALLERGA E,⁴ FERREIRO MR,⁴ CARRERA E,⁵ BARREYRO F,⁶ DIAZ-FERRER J,⁷ SINGH D,¹⁰ MATTOS AZ,⁸ CARRILHO F,⁹ DEBES J¹⁰

O-5

MICROBIOTA MODULATION BY SYMBIOTIC MODIFY GUT FLORA AND REDUCES OBESITY WITHOUT IMPROVEMENT OF FATTY LIVER IN OB OB MICE

BEZERRA-DUARTE SM,¹ TADEU-STEFANO J,¹ OLIVEIRA N,¹ FRANCO LAM,² MARTINS RC,² VELOSO-ALVES-PEREIRA I,³ SABINO EC,² COGLIATI B,³ CARRILHO FJ,¹ OLIVEIRA CP¹
¹ GASTROENTEROLOGY (LIM-07), UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE, SÃO PAULO, BRAZIL.
² INFECTIOUS DISEASE AND INSTITUTE OF TROPICAL MEDICINE, UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE, SÃO PAULO, BRAZIL.
³ DEPARTMENT OF PATHOLOGY, SCHOOL OF VETERINARY MEDICINE AND ANIMAL SCIENCE, UNIVERSITY OF SÃO PAULO, SÃO PAULO.

O-6

PLASMA PROTEOMIC SIGNATURE IN PATIENTS WITH NASH TREATED WITH OMEGA-3: PERSPECTIVES OF KNOWING MECHANISM OF ACTION

OKADA LSRR,¹ OLIVEIRA CP,¹ STEFANO JT,¹ NOGUEIRA MA,¹ SILVA IDC,² CORDEIRO FB,³ ALVES VAF,⁴ TORRINHAS RS,¹ CARRILHO FJ,¹ WAITZBERG DL¹

¹ DEPARTMENT OF GASTROENTEROLOGY (LIM-07/LIM-35), UNIVERSITY OF SAO PAULO SCHOOL OF MEDICINE, SAO PAULO, BRAZIL.

² LABORATORY OF MOLECULAR GYNECOLOGY, DEPARTMENT OF GYNECOLOGY, SAO PAULO FEDERAL UNIVERSITY, SAO PAULO, SP, BRAZIL.

³ HUMAN REPRODUCTION SECTION, DIVISION OF UROLOGY, DEPARTMENT OF SURGERY, SAO PAULO FEDERAL UNIVERSITY, SAO PAULO, BRAZIL.

⁴ DEPARTMENT OF PATHOLOGY (LIM-14), UNIVERSITY OF SAO PAULO SCHOOL OF MEDICINE, SAO PAULO, BRAZIL.

O-7

B.A.R.C.O.S. (BRAZILIAN ARGENTINE HEPATITIS C COLLABORATIVE OBSERVATIONAL STUDY) REAL WORD DATA OF HCV TREATMENT WITH DACLATASVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN

RIDRUEJO E,^{1,2,3} CHEINQUER H,^{3,4} MARCIANO S,^{5,6} MENDIZABAL M,^{2,3} HERZ WOLFF F,⁴ DE ARAUJO A,⁴ COELHO BORGES S,⁴ KLIEMANN D,⁴ GARRAZTASUL P,² BERMUDEZ C,⁵ GADANO A,^{5,6} SILVA M^{2,3}

¹ SECCIÓN DE HEPATOLOGÍA, DEPARTAMENTO DE MEDICINA. CENTRO DE EDUCACIÓN MÉDICA E INVESTIGACIONES CLÍNICAS NORBERTO QUIRNO "CEMIC". CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

² UNIDAD DE HEPATOLOGÍA Y TRASPLANTE DE HÍGADO. HOSPITAL UNIVERSITARIO AUSTRAL. PRESIDENTE DERQUI, BUENOS AIRES; ARGENTINA.

³ LATIN AMERICAN LIVER RESEARCH EDUCATIONAL AND AWARENESS NETWORK (LALREAN).

⁴ DIVISIÓN DE GASTROENTEROLOGÍA Y HEPATOLOGÍA, HOSPITAL DE CLÍNICAS DE PORTO ALEGRE, PORTO ALEGRE, BRASIL.

⁵ UNIDAD DE HÍGADO. HOSPITAL ITALIANO DE BUENOS AIRES. CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

⁶ DEPARTAMENTO DE INVESTIGACIÓN. HOSPITAL ITALIANO DE BUENOS AIRES. CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

O-8

OVERALL SURVIVAL (OS) UPDATE: 2-YEAR FOLLOW-UP FROM THE PHASE 3 RESORCE TRIAL OF REGORAFENIB FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) PROGRESSING ON SORAFENIB

SILVA M,¹ CARRILHO FJ,² MERLE P,³ GRANITO A,⁴ HUANG Y-H,⁵ BODOKY G,⁶ YOKOSUKA O,⁷ ROSMORDUC O,⁸ BREDER V,⁹ GEROLAMI R,¹⁰ MASI G,¹¹ ROSS PJ,¹² QIN S,¹³ SONG T,¹⁴ BRONOWICKI J-P,¹⁵ OLLIVIER-HOURMAND I,¹⁶ KUDO M,¹⁷ LEBERRE M-A,¹⁸ BAUMHAUER A,¹⁹ MEINHARDT G,²⁰ HAN G,²¹ BRUIX J, ON BEHALF OF THE RESORCE INVESTIGATORS²²

¹ HEPATOLOGY AND LIVER TRANSPLANT UNIT, HOSPITAL UNIVERSITARIO AUSTRAL, UNIVERSIDAD AUSTRAL, PILAR, ARGENTINA.

² DEPARTMENT OF GASTROENTEROLOGY, HOSPITAL DAS CLÍNICAS, FACULDADE DE MEDICINA, UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, BRAZIL.

³ GROUPEMENT HOSPITALIER LYON NORD, HEPATOLOGY UNIT, LYON, FRANCE.

⁴ DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES, UNIVERSITY OF BOLOGNA, S. ORSOLA-MALPIGHI HOSPITAL, BOLOGNA, ITALY.

⁵ DIVISION OF GASTROENTEROLOGY AND HEPATOLOGY, TAIPEI VETERANS GENERAL HOSPITAL; INSTITUTE OF CLINICAL MEDICINE, NATIONAL YANG-MING UNIVERSITY, TAIPEI, TAIWAN.

⁶ DEPARTMENT OF ONCOLOGY, ST. LASZLO TEACHING HOSPITAL, BUDAPEST, HUNGARY.

⁷ DEPARTMENT OF GASTROENTEROLOGY AND NEPHROLOGY, CHIBA UNIVERSITY, CHIBA, JAPAN.

⁸ DEPARTMENT OF GASTROENTEROLOGY AND HEPATOLOGY, HÔPITAL DE LA PITIÉ-SALPÊTRIÈRE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS AND UNIVERSITÉ PIERRE ET MARIE CURIE, SORBONNE UNIVERSITÉS, PARIS, FRANCE.

⁹ DEPARTMENT OF CLINICAL BIOTECHNOLOGIES, NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY N.A.N.BLOKHIN, MOSCOW, RUSSIAN FEDERATION.

¹⁰ DEPARTMENT OF HEPATOGASTROENTEROLOGY, CHU TIMONE, UNIVERSITÉ DE LA MÉDITERRANÉE, MARSEILLE, FRANCE.

¹¹ DEPARTMENT OF TRANSLATIONAL RESEARCH AND NEW TECHNOLOGIES IN MEDICINE AND SURGERY, AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, PISA, ITALY.

¹² DEPARTMENT OF MEDICAL ONCOLOGY, KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST, LONDON, UNITED KINGDOM.

¹³ DEPARTMENT OF MEDICAL ONCOLOGY, CHINESE PEOPLE'S LIBERATION ARMY CANCER CENTER OF NANJING BAYI HOSPITAL, NANJING, CHINA.

¹⁴ DEPARTMENT OF HEPATOBILIARY TUMORS, TIANJIN MEDICAL UNIVERSITY CANCER HOSPITAL, TIANJIN, CHINA.

¹⁵ HÉPATOGASTROENTÉROLOGIE, INSERM 954, CHU DE NANCY, UNIVERSITÉ DE LORRAINE, NANCY, FRANCE.

¹⁶ SERVICE D'HÉPATOGASTROENTÉROLOGIE, CHU, CAEN, FRANCE.

¹⁷ DEPARTMENT OF GASTROENTEROLOGY AND HEPATOLOGY, KINDAI UNIVERSITY FACULTY OF MEDICINE, OSAKA, JAPAN.

¹⁸ PHARMACEUTICALS DIVISION, BAYER HEALTHCARE SAS, LOOS, FRANCE.

¹⁹ PHARMACEUTICALS DIVISION, BAYER AG, LEVERKUSEN, GERMANY.

²⁰ CLINICAL DEVELOPMENT ONCOLOGY, BAYER HEALTHCARE PHARMACEUTICALS, WHIPPANY, NJ, USA.

²¹ DEPARTMENT OF LIVER DISEASE AND DIGESTIVE INTERVENTIONAL RADIOLOGY, NATIONAL CLINICAL RESEARCH CENTER FOR DIGESTIVE DISEASE, XIJING HOSPITAL OF DIGESTIVE DISEASES, XIJING HOSPITAL, FOURTH MILITARY MEDICAL UNIVERSITY, XI'AN, CHINA.

²² BCLC GROUP, LIVER UNIT, HOSPITAL CLINIC, UNIVERSITY OF BARCELONA, IDIBAPS, CIBEREHD, BARCELONA, SPAIN.

O-9

VALIDATION OF A MODEL PREDICTING PATIENT AND GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION: THE DONOR RISK INDEX (DRI), A USEFUL TOOL IN LATIN AMERICA

ZAPATA R, GINESTA A, RIUS M, GÓMEZ F, SANHUEZA E, CONTRERAS-HUMERES R, RENCORET G, VIVANCO M, PALACIOS JM

UNIDAD DE TRASPLANTE HEPÁTICO. CLÍNICA ALEMANA DE SANTIAGO. FACULTAD DE MEDICINA, UNIVERSIDAD DEL DESARROLLO. SANTIAGO, CHILE.

O-10

REAL WORD DATA OF HCV TREATMENT WITH DIRECT ACTING ANTIVIRALS FROM THE LATIN AMERICAN LIVER RESEARCH EDUCATIONAL AND AWARENESS NETWORK (LALREAN)

RIDRUEJO E,¹ MENDIZABAL M,² HUGO C,³ ANDERS M,⁴ AMEIGEIRAS B,⁵ REGGIARDO MV,⁶ ALONSO C,² VARÓN A,⁷ VIDELA ZUAIN MG,⁸ SCHINONI MI,⁹ ADROVER R,¹⁰ MARCELO SILVA M,² ON BEHALF OF LATIN AMERICAN LIVER RESEARCH EDUCATIONAL AND AWARENESS NETWORK (LALREAN)

¹ HEPATOLOGY SECTION, DEPARTMENT OF MEDICINE. CENTRO DE EDUCACIÓN MÉDICA E INVESTIGACIONES CLÍNICAS NORBERTO QUIRINO "CEMIC". CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

² HEPATOLOGY AND LIVER TRANSPLANT UNIT. HOSPITAL UNIVERSITARIO AUSTRAL. PRESIDENTE DERQUI, BUENOS AIRES; ARGENTINA.

³ GASTROENTEROLOGY AND HEPATOLOGY DIVISION, HOSPITAL DE CLÍNICAS DE PORTO ALEGRE, PORTO ALEGRE, BRAZIL.

⁴ HEPATOLOGY AND LIVER TRANSPLANT UNIT. HOSPITAL ALEMÁN. CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

⁵ GASTROENTEROLOGY AND HEPATOLOGY DIVISION, HOSPITAL RAMOS MEJÍA, CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

⁶ GASTROENTEROLOGY AND HEPATOLOGY DIVISION, HOSPITAL CENTENARIO, ROSARIO, ARGENTINA.

⁷ FUNDACIÓN CARDIOINFANTIL, INSTITUTO DE CARDIOLOGÍA, BOGOTÁ, COLOMBIA.

⁸ HEPATOLOGY UNIT. OSECAC. CIUDAD AUTÓNOMA DE BUENOS AIRES, ARGENTINA.

⁹ FEDERAL UNIVERSITY. BAHIA, BRAZIL.

¹⁰ CENTRO DE HEPATOLOGÍA. LA PALTA, ARGENTINA.